---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-22-000039"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:33:34.554379+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amgen Q2 2022: GAAP EPS $2.45, revenue $6.6B; guidance updated; non-GAAP policy change

## Summary
- Total revenues $6.6B (+1% YoY); product sales +3% driven by Repatha, Prolia, LUMAKRAS, EVENITY.
- GAAP EPS $2.45 vs $0.81 YoY; non-GAAP EPS $4.65 vs $1.77 YoY; free cash flow $1.7B flat.
- 2022 revenue guidance revised to $25.5-$26.4B; non-GAAP EPS reaffirmed $17-$18.
- Updated non-GAAP policy excludes upfront/milestone payments; prior 2021 non-GAAP EPS recast to $13.92 from $17.10.

## SEC filing metadata
- accession: 0000318154-22-000039
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/0000318154-22-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/amgn-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-22-000039
- JSON: https://secwatch.observer/filing/0000318154-22-000039.json
- Plain text: https://secwatch.observer/filing/0000318154-22-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.